Summary by Moomoo AI
Evelo Biosciences, Inc. has officially filed a Form 15 with the United States Securities and Exchange Commission (SEC) to terminate its registration under Section 12(g) of the Securities Exchange Act of 1934, as well as to suspend its duty to file reports under Sections 13 and 15(d) of the same act. The filing indicates that Evelo Biosciences will no longer be required to file periodic financial reports with the SEC. The decision to deregister was made under Rule 12g-4(a)(1) and Rule 15d-6, as marked on the form. The company reported approximately 36 holders of record as of the notice date. The certification was signed by Craig R. Jalbert, the Chief Executive Officer, President, and Director of Evelo Biosciences, on January 26, 2024.